Vice President, Biologics Development & Manufacturing at aTyr Pharma, Inc.
This person is connected to 1,152 people.
Executive Chairman at Gilead Sciences, Inc.
Independent Member of the Board of Directors at NetApp, Inc.
Former President-Human Health Europe at Merck & Co., Inc.
Vice Chair, Department of Pediatrics at University of Alabama, Birmingham - School of Medicine
Chief Executive Officer at Catholic Health Initiatives
Member, Executive Committee at California Institute of Technology
President, Director & Chief Executive Officer at Gilead Sciences, Inc.
Professor-Public Policy Program at Stanford University
President at CGI Pharmaceuticals, Inc.
Minister of State at Government of Belgium
Paths to Ashraf Amanullah
Connections via Relationship Science
Birmingham has been challenging and developing great minds for more than a century. Characterised by a tradition of innovation, research at the University has broken new ground, pushed forward the boundaries of knowledge and made an impact on people’s lives.
We continue this tradition today and have ambitions for a future that will embed our work and recognition of the Birmingham name on the international stage.
Universities are never complete. They develop as new challenges and opportunities occur. At Birmingham we innovate, we push the frontiers of understanding; we ask new research questions, we turn theory through experiment into practice – because that’s what great universities do.
The University of Sheffield
Vice President, Biologics Development & Manufacturing
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of innovative therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler in 2005 and is headquartered in San Diego, CA.
2006 - 2011
Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases and opportunistic areas. The company was founded by Herbert W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.
Boards & Committees
2011 - 2015
Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need.
In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents.
Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation
You've reached your 7 free profiles limit this month.
Upgrade to RelSci Pro today to enjoy unlimited profile views and much more!